Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER THERAPY

Combining checkpoint inhibition and targeted therapy in melanoma

The combination of BRAF and MEK inhibition and anti-PD-1 is tolerable and has promising efficacy, which warrants further investigation into its use as melanoma therapy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Combined checkpoint inhibition and targeted therapy for melanoma.

References

  1. Long, G. V. et al. J. Clin. Oncol. 36, 667–673 (2018).

    Article  CAS  Google Scholar 

  2. Larkin, J. et al. N. Engl. J. Med. 371, 1867–1876 (2014).

    Article  Google Scholar 

  3. Long, G. V. et al. Am. J. Clin. Oncol. 36, 9503–9503 (2018).

    Article  Google Scholar 

  4. Hodi, F. S. et al. Lancet Oncol. 19, 1480–1492 (2018).

    Article  CAS  Google Scholar 

  5. Ribas, A. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0476-5 (2019).

    Article  CAS  Google Scholar 

  6. Sullivan, R. J. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0474-7 (2019).

    Article  CAS  Google Scholar 

  7. Ascierto, P. A. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0448-9 (2019).

    Article  CAS  Google Scholar 

  8. Robert, L., Ribas, A. & Hu-Lieskovan, S. Semin. Immunol. 28, 73–80 (2016).

    Article  CAS  Google Scholar 

  9. Wilmott, J. S. et al. Clin. Cancer Res. 18, 1386–1394 (2012).

    Article  CAS  Google Scholar 

  10. Frederick, D. T. et al. Clin. Cancer Res. 19, 1225–1231 (2013).

    Article  CAS  Google Scholar 

  11. Hu-Lieskovan, S. et al. Sci. Transl. Med. 7, 279ra241 (2015).

    Article  Google Scholar 

  12. Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. N. Engl. J. Med. 368, 1365–1366 (2013).

    Article  CAS  Google Scholar 

  13. Minor, D. R., Puzanov, I., Callahan, M. K., Hug, B. A. & Hoos, A. Pigment Cell Melanoma Res. 28, 611–612 (2015).

    Article  Google Scholar 

  14. Deken, M. A. et al. OncoImmunology 5, e1238557 (2016).

    Article  Google Scholar 

  15. Rozeman, E. A. et al. Ann. Oncol. 29, mdy424-056 (2018).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christian U. Blank.

Ethics declarations

Competing interests

E.A.R. received travel support from MSD and NanoString. C.U.B. reports personal fees as a consultant advisor for Bristol-Myers Squibb, Merck Sharpe Dohme, Roche, Novartis, Lilly, Pfizer, GlaxoSmithKline, GenMab and Pierre Fabre and has received research grants from Bristol-Myers Squibb, Novartis, and NanoString, all paid to the institution (Netherlands Cancer Institute).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rozeman, E.A., Blank, C.U. Combining checkpoint inhibition and targeted therapy in melanoma. Nat Med 25, 879–882 (2019). https://doi.org/10.1038/s41591-019-0482-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-019-0482-7

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer